STRICTET CONTIDENTIAL

Application No: (For internal IAAF use only)



IAAF Therapeutic Use Exemptions (TUE) Application Form

I hereby apply for approval for the therapeutic use of a prohibited substance or prohibited method on the WADA Prohibited List

Please complete all sections in CAPITAL LETTERS or typing

I am included in IAAF Registered Testing Pool o	
Preparing for IAAF International Competition (v	which competition)
1. Athlete information	
First Name:	Last Name:
Female Male	Date of birth (dd/mm/yy):
Nationality:	Discipline:
Address:	
City:	Country:
Postal Code:	E-mail:
Tel.: (with international code)	Mobile:
2. Medical information	
Diagnosis with sufficient medical information (**	see Note 1):
If a permitted medication cannot be used to tre	eat the medical condition, provide clinical justification for the
requested use of the prohibited medication:	
	a contract or tubus provinces to technical and active to distribute a supplication of the contract of the cont

Document ID: **IAAF 005F-1 rev.2 [en]**File: iaaf 005f-1 rev2- tue application form.doc

Application date: April 2010

Paa. 1 of 6

STRICTLY CONFIDENTIAL

3. Medication details

Prohibited substance(s) (see Commercial name/Generic nam e.g: Humuline©/Insulin		Dose of administration	Route of administration	Frequency of administration
1.				
2.				
3.				
Intended duration of treatment	Once only		Emergency	
(see Note 3):	Or duration	(week / month):		
Have you submitted any previous				
For which substance(s)?				
Organisation (to whom TUE applic	ation was se	nt)		
When (dd/mm/yy):				
Result (attach previous TUE(s) who	ere applicabl	e): Approved	Not approved	
Has the athlete's National Federat	ion Team Do	octor been notified o	f this application?	
Yes: No:				
Name of National Federation's Te	am Doctor (see Note 4):		

STRICTLY CONFIDENTIAL

4. Medical practitioner's declaration

I certify that the above-mentioned medication(s) for the above-named athle for the above-named medical condition. I further certify that the use of alto List would be unsatisfactory for the treatment of the above-named medical Name, qualifications and medical speciality (**see Note 6):	ernative medications not on the WADA Prohibited condition (** see Note 5).
, , , , , , , , , , , , , , , , , , , ,	
Address:	
City:	
Postal Code: E-mail:	
Tel.: (with international code)	
Signature of medical practitioner:	
5. Athlete's declaration and consent	
I,	the WADA Prohibited List. I authorize the release of my cuse Exemption Sub-Commission (IAAF TUESC), as well or administration of my application in accordance with and/or members of the WADA or IOC Therapeutic Use the IAAF TUESC involved in the administration of TUE
I understand that, if I ever wish to revoke the right of the IAAF TUESC to obtain medical practitioner and the IAAF in writing of that fact. I also understand that, if medical information, I may not receive approval for a TUE or the renewal of an ewithout the disclosure of comprehensive medical data. I am aware that an applic transmission, disclosure, use and storage) of all data pertaining to such applicationsystems, including those at the IAAF and the Anti-Doping Administration and No coordinate and effective anti-doping programmes for detection, deterrence and p such processing of my TUE related data.	If I withdraw my consent to the release of my personal existing TUE, since no TUE can be granted or renewed cation for a TUE requires the processing (for example, on through relevant administration/data management Management System (ADAMS), to ensure harmonized,
I authorize for the decision of the IAAF TUESC to be notified to other relevant understand and agree that if a TUE is granted, such TUE and the related informatio period of 8 years, the period of 8 years being the period within which an action car under IAAF Rules.	n will be stored electronically in ADAMS for a minimum
WITHDRAWAL OF CONSENT	
I understand that I may at any time revoke my consent for the processing of my TU administration/data management system, including ADAMS. I understand however I will not receive approval for a TUE or a renewal of an existing TUE.	E related data through the relevant that, as a consequence of such withdrawal of consent,
RELEASE I hereby release the IAAF and the IAAF TUESC from all claims, demands, liabilities, connection with the processing of my TUE related data.	damages, costs and expenses that I may have arising in
Athlete's signature:	Date:
Parent's/Guardian's signature:	Date:
(if the athlete is a minor, a parent or guardian shall sign together with or on behalf	of the athlete)

Notes:

Note 1	Diagnosis
	Evidence confirming the diagnosis must be attached and forwarded with this application. The medical evidence should include a comprehensive medical history, and the results of all relevant clinical examinations investigations, specialist medical reports and imaging studies. Copies of original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances and, in the case of non-demonstrable conditions, independent supporting medical opinion will assist this application.
	For applications for the use of Beta-2-agonists only: To constitute a complete application , International-Level athletes must include the following documentation required by the IAAF Beta-2-Agonists Protocol:
	Detailed Medical Records Provocation Test Results
	Both must be filled in on appendix A of this Application Form
	Refer to the IAAF Beta-2 Agonists Protocol in the "athletes area" of www.iaaf.org/antidoping for further more detailed information on the documentation that is required.
Note 2	Medication details
	Provide details concerning all medications or treatments. Provide both the commercial and generic name (International Nonproprietary Name - INN) of the medication and specify the medication dose, the route of administration and the frequency of administration.
Note 3	Change of Prescription
	Note that a new TUE application is required for any change in prescription.
Note 4	
	National Federation Team Doctor
	Whenever possible, the National Federation Team Doctor should be notified of the application and the application should include a statement by the Team Doctor attesting to the necessity of the otherwise prohibited substance or prohibited method in the treatment of the athlete.
Note 5	If a permitted medication cannot be used in the treatment of the athlete's medical condition, please provide clinical justification (on page 1) for the requested use of the prohibited medication.
Note 6	Name, qualifications and medical specialty
	For example: Dr AB Cook, MD FRACP, Gastro-enterologist. Dr JA Gonzalez, MBBS, FACSM, Sports Physician

! WARNING: Incomplete Applications will be returned and will need to be re-submitted!

.......

Please submit the completed form to the IAAF Medical and Anti-Doping Department (see contact details below) and keep a copy of the form for your records:

IAAF Medical and Anti-Doping Department

17, Rue Princesse Florestine

BP 359 - MC 98007

Monaco

Confidential Fax: +377 93 50 83 95

If there are further questions arising from this Form or regarding the relevant procedures for standard applications for TUEs, please contact the IAAF for further information on: +377 93 10 88 89 (tel) or tue-application@iaaf.org (e-mail).

Document ID: IAAF 005F-1 rev.2 [en]

Application date: April 2010

Paa. 5 of 6

STRICTLY CONFIDENTIAL

Appendix A

IAAF INHALED BETA-2-AGONIST APPLICATION FOR ASTHMA TREATMENT **Medical Records FORM**

		COUNTRY:	
DATE OF BIRTH.			
iagnosis:			
ge of onset:			
mptoms spontaneous or exercise re	lated:	D	Yes or No
oughing during or post-exercise:	Yes or No	Dyspnoea: Wheezing:	Yes or No
nortness of breath:	Yes or No		Yes or No
nest tightness:	Yes or No	Excess sputum:	
yes, specify:			
lentified triggering factors :			
ast history of atopic disorders and/o	or childhood asthm	a:	
ast physical examinations:			
esults of skin prick tests or RAST to	document the pres	ence of allergic hyperser	sitivity:
Details of all consultations with quali	fied physicians in t	he treatment of asthma:	
Details of any attendance in hospit	al emergency dep	artments for treatment	or admission to hospital for treatmer
acute exacerbation of asthma.			or admission to hospital for treatmen
acute exacerbation of asthma.	prescribed medica		dication prescribed in the past years,
acute exacerbation of asthma. Details of the individual's currently particular details in the last 6 month	prescribed medica	ation and any other me	
acute exacerbation of asthma. Details of the individual's currently	prescribed medica	ation and any other me	
acute exacerbation of asthma. Details of the individual's currently particular details in the last 6 month	prescribed medica	ation and any other me	
ocute exacerbation of asthma. Details of the individual's currently particular details in the last 6 month	prescribed medica	ation and any other me	
acute exacerbation of asthma. Details of the individual's currently particular details in the last 6 month on the 3 month of the 1 month of the 1 month of the 3 month of the 4 month of	prescribed medica	ation and any other me	
Details of the individual's currently particular details in the last 6 month Details of medication in the 3 month	prescribed medica s. ns prior to provocat	ation and any other me tion test:	dication prescribed in the past years,
Details of the individual's currently particular details in the last 6 month Details of medication in the 3 month PFTesting information Bronchodilator test: FE	prescribed medicals. In prior to provocate In after bronchodical	ation and any other me tion test:	dication prescribed in the past years,
Details of the individual's currently particular details in the last 6 month Details of medication in the 3 month PFTesting information Bronchodilator test: FE	prescribed medicals. In prior to provocate In after bronchodicals.	nation and any other me	dication prescribed in the past years, est: / / ed to baseline: %
Details of the individual's currently particular details in the last 6 month Details of medication in the 3 month PFTesting information Bronchodilator test: FEN Methacholine challenge	prescribed medicals. In prior to provocate In after bronchodicals.	Date of to	est:/
PFTesting information Bronchodilator test: FE\ Methacholine challenge	prescribed medicals. In prior to provocate In after bronchode test In after bronchode test	Date of to	est: /
PFTesting information Bronchodilator test: FEN Methacholine challenge PD20 =	prescribed medicals. In a prior to provocate for the state of the st	Date of to later: change compared of the compa	est: /
PFTesting information Bronchodilator test: FEN Methacholine challenge PD ₂₀ =	prescribed medicals. In a prior to provocate for the provocate f	Date of to later: change compare of	est: /
PFTesting information Bronchodilator test: FEN Methacholine challenge PD20 =	prescribed medicals. In a prior to provocate for the provocate f	Date of to later: change compare of	est: /
PFTesting information Bronchodilator test: FEN Methacholine challenge PD ₂₀ =	prescribed medicals. In a prior to provocate the state ofμg / 1 decrease of	Date of to later: change compare of	est: /
PFTesting information Bronchodilator test: FEN Methacholine challenge PD20 =	prescribed medicals. In a prior to provocate the state ofμg / 1 decrease of	Date of to later change compared precises of % within	est: /